Patent · US Active

N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide

US7659286B2 · kind B2 · utility

3Cited by

10References

5Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Cathy Dantzman · Wilmington, US
Glen Ernst · Bear, US
Megan Murphy King · Wilmington, US

Key dates

Filing date	Oct 19, 2007
Grant date	Feb 9, 2010
Priority date	—
Expiry date	Oct 19, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.